LIFECORE BIOMEDICAL INC
LFCRNASDAQTrading Snapshot
- Day Range
- $6.31 β $6.50
- 52-Week Range
- $3.63 β $8.98
- Volume (shares)
- 1,023,939
- Avg Volume (shares)
- β
- Shares Outstanding
- 37.9M
- Next Earnings
- 2027-02-05
Fundamentals Snapshot
- Annual Revenue
- $129M
- Last Q Revenue
- $34M
- P/E Ratio
- β
- P/S Ratio
- 1.5x
- EPS (TTM)
- $-1.31
- Dividend Yield
- β
- Dilution (1yr)
- +8.9%
LIFECORE BIOMEDICAL INC
LFCRAbout LIFECORE BIOMEDICAL INC
Lifecore Biomedical, Inc., together with its subsidiaries, operates as an integrated contract development and manufacturing organization that serves customers in the United States, Belgium, the Netherlands, and internationally. It provides services in the development, manufacture, aseptic fill, and finish of formulations and highly viscous sterile injectable pharmaceutical drug or medical device products in syringes, vials, and cartridges in various modalities. The company also manufactures and sells pharmaceutical-grade hyaluronic acid in bulk form, as well as for use in formulated and filled syringes and vials for injectable products used in treating various medical conditions and procedures, including ophthalmic and orthopedic applications. In addition, it offers product development services, including analytical method development and validation, formulation development, sterile filtration, process scale-up, pilot studies, stability studies, process validation, and materials production for clinical studies. The company was formerly known as Landec Corporation and changed its name to Lifecore Biomedical, Inc. in November 2022. Lifecore Biomedical, Inc. was founded in 1965 and is headquartered in Chaska, Minnesota.
Otter Score Breakdown
How it's scoredFive components, each rated 1β5β and equally weighted (20%), averaged to a 0β100 score:π Quality β gross marginπ Growth β revenue YoYβοΈ Valuation β P/S ratioβ‘ Momentum β 30-day price changeπ§ Dilution β 1-yr share issuance (buybacks score higher)Insufficient data for all five components.
Analyst Ratings
βLatest News & Updates

BRODSKY & SMITH SHAREHOLDER UPDATE: Notifying Investors of the Following Investigations: ADT Inc. (NYSE β ADT), RXO Inc. (NYSE β RXO), PTC Inc. (Nasdaq β PTC), Lifecore Biomedical, Inc. (Nasdaq β LFCR)
BALA CYNWYD, Pa., Oct. 30, 2026 (GLOBE NEWSWIRE) -- Brodsky & Smith reminds investors of the following investigations. If you own shares and wish to discuss the investigation, contact Jason Brodsky (jbrodsky@brodskysmith

Lifecore Biomedical to Participate at Upcoming Industry Conferences
CHASKA, Minn., Oct. 07, 2026 (GLOBE NEWSWIRE) -- Lifecore Biomedical, Inc. (NASDAQ:Β LFCR) (βLifecoreβ), a fully integrated injectables contract development and manufacturing organization (βCDMOβ), today announced that th

Are RXO, PTC, LFCR, WAFD Obtaining Fair Deals for their Shareholders?
Are RXO, PTC, LFCR, WAFD Obtaining Fair Deals for their Shareholders?PR NewswireNEW YORK, Oct. 5, 2026Insiders may stand to receive substantial financial benefi

BRODSKY & SMITH SHAREHOLDER UPDATE: Notifying Investors of the Following Investigations: RXO Inc. (NYSE β RXO), PTC Inc. (Nasdaq β PTC), Lifecore Biomedical, Inc. (Nasdaq β LFCR), WaFd, Inc. (Nasdaq β WAFD)
BALA CYNWYD, Pa., Oct. 05, 2026 (GLOBE NEWSWIRE) -- Brodsky & Smith reminds investors of the following investigations. If you own shares and wish to discuss the investigation, contact Jason Brodsky (jbrodsky@brodskysmith

EQUITY ALERT - The M&A Class Action Firm Launches Inquiry -- FWAC, MGLD, LFCR, and MG
EQUITY ALERT - The M&A Class Action Firm Launches Inquiry -- FWAC, MGLD, LFCR, and MGPR NewswireNEW YORK, Oct. 3, 2026NEW YORK, Oct. 3, 2026 /PRNewswire/ --Clas

Halper Sadeh LLC is Investigating Whether LFCR and SSTI are Obtaining Fair Deals for their Shareholders
Insiders may stand to receive substantial financial benefits not available to ordinary shareholders.